Drug name - Zyclara

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238645 BAUSCH Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts Aug, 2029

(6 years from now)

US8598196 BAUSCH Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy Aug, 2029

(6 years from now)

US8299109 BAUSCH Method of treating actinic keratosis with 3.75% imiquimod cream Dec, 2029

(7 years from now)

US8236816 BAUSCH 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod Dec, 2029

(7 years from now)

US8222270 BAUSCH 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod Dec, 2029

(7 years from now)

US10238644 BAUSCH 2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod Dec, 2029

(7 years from now)

US10918635 BAUSCH Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts Apr, 2030

(7 years from now)

US11202752 BAUSCH Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy Apr, 2030

(7 years from now)

Drugs and Companies using IMIQUIMOD ingredient

Treatment: Treatment of genital warts; treatment of perianal warts; Treatment of actinic keratosis; Treatment of perianal warts; treatment of genital warts

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
2.5% CREAM;TOPICAL Prescription
3.75% CREAM;TOPICAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.